170 related articles for article (PubMed ID: 29190725)
1. Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico.
Ortiz AP; Ortiz-Ortiz KJ; Ríos M; Laborde J; Kulkarni A; Pillsbury M; Lauschke A; Monsanto HA; Marques-Goyco C
PLoS One; 2017; 12(11):e0184540. PubMed ID: 29190725
[TBL] [Abstract][Full Text] [Related]
2. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
[TBL] [Abstract][Full Text] [Related]
9. The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia.
Uusküla A; Müürsepp A; Kawai K; Raag M; Jürisson M; Pillsbury M
BMC Infect Dis; 2013 Jul; 13():304. PubMed ID: 23819789
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan.
Yamabe K; Singhal PK; Abe M; Dasbach EJ; Elbasha EH
Value Health Reg Issues; 2013 May; 2(1):92-97. PubMed ID: 29702859
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
13. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
15. Knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination among Puerto Rican mothers and daughters, 2010: a qualitative study.
Fernández ME; Le YC; Fernández-Espada N; Calo WA; Savas LS; Vélez C; Aragon AP; Colón-López V
Prev Chronic Dis; 2014 Dec; 11():E212. PubMed ID: 25474384
[TBL] [Abstract][Full Text] [Related]
16. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
18. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark.
Olsen J; Jepsen MR
Int J Technol Assess Health Care; 2010 Apr; 26(2):183-91. PubMed ID: 20392322
[TBL] [Abstract][Full Text] [Related]
20. Age-based programs for vaccination against HPV.
Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
